Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 13/20 | 0.55 |
| ▸ | CTSS | P25774 | 7/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5438237 | 1.00 | CTSK (0.55) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL18354057 | 0.86 | GAA (0.44) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL836447 | 0.85 | JAK3 (0.52) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL6631742 | 0.85 | JAK3 (0.52) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL836446 | 0.85 | JAK3 (0.52) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL14496975 | 0.85 | CTSK (0.43) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL14842208 | 0.85 | CTSK (0.43) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL24924763 | 0.83 | CTSK (0.43) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL3213287 | 0.83 | CTSS (0.46) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL14779393 | 0.83 | CTSK (0.57) | CTSKCTSSCYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678760-B2 | Inhibitors of Memapsin 2 and use thereof | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2010-03-16 | — | — | US | disclosed |
| US-20080021196-A1 | INHIBITORS OF MEMAPSIN 2 AND USE THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021196-A1 | INHIBITORS OF MEMAPSIN 2 AND USE THEREOF | PSEN2, APP, ANPEP | CTSK 2847/4885CTSS 2264/4885CYP1A2 3213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.